Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | GPR3 | P46089 | 4/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14126262 | 0.81 | AKR1C3 (0.54) | PPARGPPARAFFAR4 | |
| SCHEMBL16429063 | 0.81 | ALOX5 (0.55) | GPR3ESR2FFAR4METAP2CHRM5 | |
| SCHEMBL27907854 | 0.81 | ALOX5AP (0.51) | GPR3FFAR4METAP2CHRM5CYP1A2 | |
| SCHEMBL16727887 | 0.79 | GPR3 (0.55) | SCN5AGPR3ESR2FFAR4KIF11 | |
| SCHEMBL27926260 | 0.79 | GPR3 (0.49) | SCN5AGPR3FFAR4METAP2CHRM5 | |
| SCHEMBL16099410 | 0.79 | GPR3 (0.49) | SCN5AGPR3METAP2CHRM5CYP1A2 | |
| SCHEMBL27908024 | 0.79 | GPR3 (0.49) | GPR3FFAR4METAP2CHRM5CHRM1 | |
| SCHEMBL5535236 | 0.79 | S1PR1 (0.44) | SCN5AGPR3PPARGPPARAFFAR4 | |
| SCHEMBL30832998 | 0.79 | METAP2 (0.43) | SCN5AGPR3PPARGPPARAFFAR4 | |
| SCHEMBL22621242 | 0.79 | SCN5A (0.48) | SCN5AGPR3FFAR4CHRM5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905230-B2 | Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-02-20 | — | — | US | disclosed |
| CN-107231794-A | Dianhydrogalactitol for use in combination with radiation in the treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2017-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905230-B2 | Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament | SLC5A1, PYGL, GPR119 | SCN5A 1380/4885GPR3 2348/4885ESR2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.